MS (Multiple Sclerosis)

New MS (Multiple Sclerosis) drug life-threatening

For a drug that’s based on rat antibodies, it’s not surprising that doctors are already starting to report life-threatening side effects in patients taking the new multiple sclerosis (MS) drug Lemtrada (alemtuzumab).

Inflammation in their brains
Two MS patients started to decline rapidly after they were given Lemtrada, and [highlight]MRI scans revealed that a new form of inflammation had affected large areas of their brains[/highlight]. The doctors at St Josef’s Hospital at Ruhr University in Bochum weren’t sure if the drug had worsened the MS or whether it had triggered a new type of auto-immune disease.

Not that Lemtrada is exactly new. It was developed as a cancer drug under the name Campath, but researchers at Genzyme, the drug company that developed it, thought it could work better as an MS therapy. Campath was withdrawn from the US and European markets in 2012 to make way for its relaunch as Lemtrada for treating MS, and at a much higher price.

The drug was licensed in 2013 in Europe as an MS drug, but [highlight]America’s drug regulators were less keen, arguing that its safety hadn’t been established by any good clinical trials[/highlight]. It was only when Genzyme threatened to file an appeal that the regulator, the Food and Drug Administration (FDA), agreed to grant a license in 2014.

Source: The Lancet Neurology 2017; 16: 104-6 doi:10.1016/S1474-4422(16)30382-9

Erkin Oksak

Ik vind dat mensen zich bewust moeten zijn van wat ze eten en in hun lichaam binnenkrijgen. In mijn ogen levert de voedingsindustrie een belangrijke bijdrage aan de huidige chronische ziekten in onze samenleving. Goede voeding, geen medicijnen, is de sleutel tot een goede gezondheid. Klik hier voor mijn persoonlijk verhaal en motivatie »
Hou me op de hoogte van

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Inline Feedbacks
View all comments
Back to top button
Would love your thoughts, please comment.x